Mycosis Fungoides Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major mycosis fungoides markets are expected to exhibit a CAGR of 4.9% during 2024-2034.
The mycosis fungoides market has been comprehensively analyzed in IMARC's new report titled "Mycosis Fungoides Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mycosis fungoides refers to a rare type of non-Hodgkin lymphoma that primarily affects the skin. It is categorized as a form of cutaneous T-cell lymphoma, arising from malignant T-cells in the skin's outer layer. This disease often presents challenges in diagnosis due to its variable and insidious nature. The symptoms of mycosis fungoides typically manifest in stages, with the initial phase resembling eczema-like skin changes, such as redness, itching, and sometimes raised patches. As the disease progresses, more pronounced indications like thickened, scaly, or ulcerated skin patches, tumors, and lymph node enlargement can occur. In advanced cases, the lymphoma may spread to various other organs. Diagnosing mycosis fungoides involves a combination of clinical evaluation, skin biopsies, and several laboratory tests. Dermatologists and oncologists analyze the skin's appearance, texture, and symptoms while also conducting biopsies to examine the presence of abnormal T-cells. Advanced techniques, like immunophenotyping and molecular studies might be conducted for definitive confirmation.
The increasing incidences of immune system dysfunction, causing the buildup of malignant white blood cells in the skin, are primarily driving the mycosis fungoides market. In addition to this, the inflating utilization of efficacious therapeutics, such as methotrexate, interferons, and retinoids, is also creating a positive outlook for the market. These medications are pivotal in managing symptoms, slowing disease progression, and alleviating discomfort, thereby enhancing the quality of life for patients. Moreover, the widespread adoption of phototherapy, since it involves the application of ultraviolet light to target affected skin cells, is further bolstering the market growth. Apart from this, the rising usage of radiation therapy, particularly for localized plaques and tumors, due to its effectiveness in reducing the proliferation of cancerous cells with minimal systemic side effects, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive care measures, such as topical corticosteroids and emollients, to alleviate symptoms like itchiness, redness, and discomfort in patients is also augmenting the market growth. Furthermore, the escalating demand for innovative treatment modalities, including extracorporeal photopheresis, which involves the removal, treatment, and reinfusion of a patient's blood to stimulate immune responses against cancerous cells, is expected to drive the mycosis fungoides market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the mycosis fungoides market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mycosis fungoides and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mycosis fungoides market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mycosis fungoides market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mycosis fungoides market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current mycosis fungoides marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the mycosis fungoides market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the mycosis fungoides market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the mycosis fungoides market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of mycosis fungoides across the seven major markets?
What is the number of prevalent cases (2018-2034) of mycosis fungoides by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of mycosis fungoides by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with mycosis fungoides across the seven major markets?
What is the size of the mycosis fungoides patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of mycosis fungoides?
What will be the growth rate of patients across the seven major markets?
Mycosis Fungoides: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for mycosis fungoides drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mycosis fungoides market?
What are the key regulatory events related to the mycosis fungoides market?
What is the structure of clinical trial landscape by status related to the mycosis fungoides market?
What is the structure of clinical trial landscape by phase related to the mycosis fungoides market?
What is the structure of clinical trial landscape by route of administration related to the mycosis fungoides market?
The mycosis fungoides market has been comprehensively analyzed in IMARC's new report titled "Mycosis Fungoides Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mycosis fungoides refers to a rare type of non-Hodgkin lymphoma that primarily affects the skin. It is categorized as a form of cutaneous T-cell lymphoma, arising from malignant T-cells in the skin's outer layer. This disease often presents challenges in diagnosis due to its variable and insidious nature. The symptoms of mycosis fungoides typically manifest in stages, with the initial phase resembling eczema-like skin changes, such as redness, itching, and sometimes raised patches. As the disease progresses, more pronounced indications like thickened, scaly, or ulcerated skin patches, tumors, and lymph node enlargement can occur. In advanced cases, the lymphoma may spread to various other organs. Diagnosing mycosis fungoides involves a combination of clinical evaluation, skin biopsies, and several laboratory tests. Dermatologists and oncologists analyze the skin's appearance, texture, and symptoms while also conducting biopsies to examine the presence of abnormal T-cells. Advanced techniques, like immunophenotyping and molecular studies might be conducted for definitive confirmation.
The increasing incidences of immune system dysfunction, causing the buildup of malignant white blood cells in the skin, are primarily driving the mycosis fungoides market. In addition to this, the inflating utilization of efficacious therapeutics, such as methotrexate, interferons, and retinoids, is also creating a positive outlook for the market. These medications are pivotal in managing symptoms, slowing disease progression, and alleviating discomfort, thereby enhancing the quality of life for patients. Moreover, the widespread adoption of phototherapy, since it involves the application of ultraviolet light to target affected skin cells, is further bolstering the market growth. Apart from this, the rising usage of radiation therapy, particularly for localized plaques and tumors, due to its effectiveness in reducing the proliferation of cancerous cells with minimal systemic side effects, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive care measures, such as topical corticosteroids and emollients, to alleviate symptoms like itchiness, redness, and discomfort in patients is also augmenting the market growth. Furthermore, the escalating demand for innovative treatment modalities, including extracorporeal photopheresis, which involves the removal, treatment, and reinfusion of a patient's blood to stimulate immune responses against cancerous cells, is expected to drive the mycosis fungoides market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the mycosis fungoides market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mycosis fungoides and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mycosis fungoides market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mycosis fungoides market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mycosis fungoides market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current mycosis fungoides marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the mycosis fungoides market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the mycosis fungoides market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the mycosis fungoides market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of mycosis fungoides across the seven major markets?
What is the number of prevalent cases (2018-2034) of mycosis fungoides by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of mycosis fungoides by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with mycosis fungoides across the seven major markets?
What is the size of the mycosis fungoides patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of mycosis fungoides?
What will be the growth rate of patients across the seven major markets?
Mycosis Fungoides: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for mycosis fungoides drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mycosis fungoides market?
What are the key regulatory events related to the mycosis fungoides market?
What is the structure of clinical trial landscape by status related to the mycosis fungoides market?
What is the structure of clinical trial landscape by phase related to the mycosis fungoides market?
What is the structure of clinical trial landscape by route of administration related to the mycosis fungoides market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MYCOSIS FUNGOIDES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MYCOSIS FUNGOIDES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MYCOSIS FUNGOIDES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MYCOSIS FUNGOIDES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MYCOSIS FUNGOIDES - UNMET NEEDS
10 MYCOSIS FUNGOIDES - KEY ENDPOINTS OF TREATMENT
11 MYCOSIS FUNGOIDES - MARKETED PRODUCTS
11.1 List of Mycosis Fungoides Marketed Drugs Across the Top 7 Markets
11.1.1 Adcetris (Brentuximab vedotin) - Seagen/Takeda Oncology
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Poteligeo (Mogamulizumab) - Kyowa Kirin
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Valchlor (Chlormethine) - Actelion Pharmaceuticals/Helsinn
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Jylamvo (Methotrexate) - Therakind
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 MYCOSIS FUNGOIDES - PIPELINE DRUGS
12.1 List of Mycosis Fungoides Pipeline Drugs Across the Top 7 Markets
12.1.1 AFM 13 - Affimed Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 HyBryte - Soligenix
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Resminostat - 4SC
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Lacutamab - Innate Pharma
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 MT 101 - Myeloid Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. MYCOSIS FUNGOIDES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MYCOSIS FUNGOIDES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MYCOSIS FUNGOIDES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Mycosis Fungoides - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Mycosis Fungoides - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Mycosis Fungoides - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Mycosis Fungoides - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Mycosis Fungoides - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Mycosis Fungoides - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Mycosis Fungoides - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Mycosis Fungoides - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Mycosis Fungoides - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Mycosis Fungoides - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Mycosis Fungoides - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Mycosis Fungoides - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Mycosis Fungoides - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Mycosis Fungoides - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Mycosis Fungoides - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Mycosis Fungoides - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Mycosis Fungoides - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Mycosis Fungoides - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Mycosis Fungoides - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Mycosis Fungoides - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Mycosis Fungoides - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Mycosis Fungoides - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Mycosis Fungoides - Access and Reimbursement Overview
16 MYCOSIS FUNGOIDES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MYCOSIS FUNGOIDES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MYCOSIS FUNGOIDES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MYCOSIS FUNGOIDES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MYCOSIS FUNGOIDES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MYCOSIS FUNGOIDES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MYCOSIS FUNGOIDES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MYCOSIS FUNGOIDES - UNMET NEEDS
10 MYCOSIS FUNGOIDES - KEY ENDPOINTS OF TREATMENT
11 MYCOSIS FUNGOIDES - MARKETED PRODUCTS
11.1 List of Mycosis Fungoides Marketed Drugs Across the Top 7 Markets
11.1.1 Adcetris (Brentuximab vedotin) - Seagen/Takeda Oncology
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Poteligeo (Mogamulizumab) - Kyowa Kirin
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Valchlor (Chlormethine) - Actelion Pharmaceuticals/Helsinn
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Jylamvo (Methotrexate) - Therakind
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 MYCOSIS FUNGOIDES - PIPELINE DRUGS
12.1 List of Mycosis Fungoides Pipeline Drugs Across the Top 7 Markets
12.1.1 AFM 13 - Affimed Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 HyBryte - Soligenix
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Resminostat - 4SC
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Lacutamab - Innate Pharma
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 MT 101 - Myeloid Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. MYCOSIS FUNGOIDES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MYCOSIS FUNGOIDES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MYCOSIS FUNGOIDES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Mycosis Fungoides - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Mycosis Fungoides - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Mycosis Fungoides - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Mycosis Fungoides - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Mycosis Fungoides - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Mycosis Fungoides - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Mycosis Fungoides - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Mycosis Fungoides - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Mycosis Fungoides - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Mycosis Fungoides - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Mycosis Fungoides - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Mycosis Fungoides - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Mycosis Fungoides - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Mycosis Fungoides - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Mycosis Fungoides - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Mycosis Fungoides - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Mycosis Fungoides - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Mycosis Fungoides - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Mycosis Fungoides - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Mycosis Fungoides - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Mycosis Fungoides - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Mycosis Fungoides - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Mycosis Fungoides - Access and Reimbursement Overview
16 MYCOSIS FUNGOIDES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MYCOSIS FUNGOIDES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MYCOSIS FUNGOIDES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
